Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects With Chronic Hepatitis B Infection

NCT04980482 is registered in ClinicalTrials.gov with Arbutus Biopharma Corporation as lead sponsor.

NCT NCT04980482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04980482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects With Chronic Hepatitis B Infection
Lead sponsor
Arbutus Biopharma Corporation
Phase
Phase 2
Overall status
Completed
Start date
October 29, 2021
Completion date
May 21, 2025
Enrollment
43 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b